24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ERLOLIEVA 150MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ERLOLIEVA 150MG |
|---|---|
| Composition | Erlotinib Tablets IP 150mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (30 tab) |
| Country of Origin | India |
Erlotinib Tablets IP 150mg (Erlotinib Tablets IP 150mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) is a targeted anticancer medicine used in the treatment of certain types of lung cancer and pancreatic cancer. It contains Erlotinib Hydrochloride, a highly effective Epidermal Growth Factor Receptor (EGFR) inhibitor that helps slow down the growth and spread of cancer cells in the body. This medicine is commonly prescribed by oncologists as part of modern targeted cancer therapy protocols for patients with specific cancer types and genetic profiles.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. In some cancers, proteins known as Epidermal Growth Factor Receptors (EGFR) play an important role in helping cancer cells survive, multiply, and spread. ERLOLIEVA 150 MG works by blocking these receptors, thereby interfering with cancer cell growth and reducing tumor progression.
Unlike traditional chemotherapy, Erlotinib is a targeted therapy that focuses on specific pathways involved in cancer development. This targeted approach helps improve treatment effectiveness in eligible patients while minimizing damage to healthy cells. As a result, Erlotinib has become an important treatment option in oncology care, especially for patients with EGFR-positive cancers.
ERLOLIEVA 150 MG is commonly prescribed for:
• Non-Small Cell Lung Cancer (NSCLC)
• EGFR Mutation-Positive Lung Cancer
• Advanced or Metastatic Lung Cancer
• Pancreatic Cancer (in combination with other treatments)
• Long-term targeted oncology treatment programs
This medicine may be used as a first-line treatment or after other cancer therapies depending on the patient's condition, treatment history, and medical requirements.
ERLOLIEVA 150 MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and consistent therapeutic performance. It is intended strictly for use under the supervision of qualified healthcare professionals experienced in oncology treatment.
Patients receiving Erlotinib therapy may require regular medical monitoring, blood tests, liver function assessments, and imaging studies during treatment. Proper monitoring helps evaluate treatment response and manage potential side effects effectively.
Due to its effectiveness in targeted oncology therapy, ERLOLIEVA 150 MG has become an important medicine in modern cancer care and personalized treatment programs.
ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) is primarily used for the treatment and management of specific types of cancer.
ERLOLIEVA is widely used in the treatment of non-small cell lung cancer, one of the most common forms of lung cancer.
Doctors often prescribe Erlotinib for patients whose cancer cells contain specific EGFR gene mutations that make them suitable candidates for targeted therapy.
The medicine is commonly used in advanced or metastatic lung cancer to help slow disease progression and improve treatment outcomes.
ERLOLIEVA may be prescribed in combination with other medicines for the treatment of advanced pancreatic cancer.
Targeted therapy with Erlotinib may help support long-term disease control and cancer management in eligible patients.
The medicine is frequently included in personalized cancer treatment plans based on genetic testing and biomarker analysis.
Erlotinib belongs to a class of medicines known as EGFR Tyrosine Kinase Inhibitors (TKIs).
ERLOLIEVA works by:
• Blocking Epidermal Growth Factor Receptors (EGFR)
• Interrupting cancer cell signaling pathways
• Preventing abnormal cell growth
• Slowing tumor progression
• Helping reduce the spread of cancer cells
This targeted mechanism allows oncologists to manage certain cancers more effectively and improve treatment outcomes in selected patients.
Like other targeted cancer therapies, ERLOLIEVA 150 MG may cause side effects in some patients. Side effects can vary depending on individual health conditions, treatment duration, and response to therapy.
Skin rash is one of the most commonly reported side effects of Erlotinib therapy.
Patients may experience loose stools or digestive discomfort during treatment.
Tiredness, weakness, or low energy levels may occur during therapy.
Some individuals may notice reduced appetite or changes in eating habits.
Mild nausea or stomach discomfort may develop during treatment.
Patients may experience skin dryness, itching, or irritation.
Mouth ulcers or oral discomfort may occur in some cases.
Hair thinning or changes in hair texture may be observed during therapy.
Some patients may experience gradual weight loss during treatment.
Although less common, some serious side effects may require immediate medical attention.
• Severe breathing difficulty
• Persistent cough
• Chest pain
• Severe diarrhea
• Serious skin reactions
• Eye pain or vision changes
• Severe allergic reactions
• Signs of liver problems
Patients should contact their healthcare provider immediately if serious symptoms develop during treatment.
The dosage of ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) should always be determined by a qualified healthcare professional based on the patient’s condition and treatment plan.
The specific cancer diagnosis plays a major role in dosage planning.
The patient’s age, weight, liver function, and general health influence treatment decisions.
Doctors may adjust treatment depending on how the patient responds to Erlotinib therapy.
Certain medicines may interact with Erlotinib and require dosage adjustments.
Dosage modifications may be necessary if significant side effects occur during treatment.
• Take the tablet exactly as prescribed by your doctor.
• Swallow the tablet whole with water.
• Do not crush, chew, or break the tablet.
• Take the medicine at the same time each day.
• Follow the treatment schedule carefully.
• Do not stop treatment without medical advice.
Patients should attend all follow-up appointments and monitoring visits during therapy.
Before starting treatment, patients should inform their doctor if they have:
• Liver disease
• Kidney disorders
• Lung problems
• Eye disorders
• Smoking history
• Previous cancer treatment complications
Patients should also discuss all prescription medicines, supplements, and herbal products they are taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Advanced targeted cancer therapy
• Effective EGFR inhibitor formulation
• Trusted oncology treatment support
• Reliable long-term cancer management
• Manufactured under strict pharmaceutical standards
• Suitable for modern personalized cancer treatment programs
It is mainly used for the treatment of non-small cell lung cancer and certain cases of pancreatic cancer.
Erlotinib is a targeted anticancer medicine that blocks EGFR activity to help slow cancer growth.
No, Erlotinib is considered a targeted therapy medicine rather than traditional chemotherapy.
Yes, skin rash is one of the most common side effects associated with Erlotinib treatment.
Doctors may recommend EGFR mutation testing to determine whether Erlotinib is an appropriate treatment option.
No, treatment should only be stopped under the guidance of a healthcare professional.
Yes, regular medical monitoring and follow-up assessments are important during treatment.
Yes, this medicine should always be used under the supervision of qualified healthcare professionals experienced in oncology care.